ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic

By sjmartinez • October 31, 2024

Keshtkar-Jahromi M, Anstrom KJ, Barkauskas C, Brown SM, Daar ES, Fischer W, Gibbs KW, Higgs ES, Hughes MD, Jagannathan P, LaVange L, Lindsell CJ, Nayak SU, Paredes R, Parmar M, Peltan ID, Proschan M, Shotwell MS, Vock DM, Yokum T, Adam SJ. ACTIV trials: Lessons learned in trial design in the setting of an emergent pandemic. J Clin Transl Sci. 2024 Oct 15;8(1):e151. doi: 10.1017/cts.2024.1. PMID: 39478775; PMCID: PMC11523015.

Tags: ACTIV, Clinical Trial, covid-19, design, Infectious Diseases, lessons, Publications

Implementation of a One Health Surveillance System in the Democratic Republic of the Congo

Kinzie PR, Lombe B, Merritt S, Halbrook M, Vakaniaki EH, Mukadi P, L'k'ye AM, Mona J, Kanonge D, Mfwangkang M, Witte D, Melofchik C, Muyembe-Tamfum[...]

Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial

Ramaswami R, Nordwall JA, Gilbert D, Kitchell E, Timiryasova A, Mitsuyasu R, Phillips AN, Lundgren J, Grabar S. Early antiretroviral therapy and long-term cancer risk[...]

Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda

Nasuuna EM, Hoffman R, Kalyesubula R, Chikwari CD, Weiss HA. Kidney abnormalities in young people living with HIV on dolutegravir-based regimens in Kampala, Uganda. AIDS[...]